It was found that sodium neutral amino acid transporters (SLC38A1/2) and L-type amino acid transporters (LAT1/SLC7A5) could be inhibited by 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids (AABA) upon SLC1A5 depletion in osteosarcoma cells and breast cancer cells, thereby suppressing cancer progression (46). Here, SLC7A5 is linked to osteosarcoma.